Bayer’s Sweeping Executive Cuts, Wegovy’s Expanding Reach
27 Mar 2024
Phase 1Drug ApprovalAHA
It was another busy week in biopharma last week, with one of the biggest announcements coming from Bayer. As part of a major restructuring, the company has reduced its executive suite from 14 to 8, among other changes. Could it be a sign that Big Pharma is following a trend in biotech toward leaner or fractional C-suites?
Meanwhile, Medicare coverage of the ever-popular GLP-1 weight-loss drugs made headlines as the government announced it will pay for Wegovy for patients with heart disease after the Novo Nordisk therapy was approved earlier this month for the cardiovascular indication. BioSpace will be keeping an eye out for indications that the government could change its tune on coverage of Wegovy and competitor Zepbound, from Eli Lilly, specifically for weight loss. This question will become all the more important if experimental oral GLP-1 drugs such as the one in Phase I development by Viking Therapeutics make it to the market.
Finally, we touch on Mirador’s emergence from stealth and the FDA’s approval of the third therapy for Duchenne muscular dystrophy in less than a year.
Greg Slabodkin is the News Editor at BioSpace. You can reach him at greg.slabodkin@biospace.com. Follow him on LinkedIn.
Heather McKenzie is a senior editor at BioSpace. You can reach her at heather.mckenzie@biospace.com. Follow her on LinkedIn.
Tyler Patchen is a staff writer at BioSpace. You can reach him at tyler.patchen@biospace.com. Follow him on LinkedIn.
> Listen on Spotify
> Listen on Apple Podcasts
> Listen on Amazon Music
> Listen on iHeart
Editor’s note: At 4:13, Al Sandrock was referred to in error. The executive in reference is John Maraganore.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.